Combination therapy of a long-acting TRAIL variant and tumor cell-targeted PDT exerted promising antitumor effects in mice bearing tumor grafts of different CRC cells (Moan & Berg, 1991; Dysart & Patterson, 2005; Mitsunaga et al., 2011; She et al., 2021). Here, TNFSF10 is linked to neoplasm.